MX2022009009A - Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. - Google Patents

Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.

Info

Publication number
MX2022009009A
MX2022009009A MX2022009009A MX2022009009A MX2022009009A MX 2022009009 A MX2022009009 A MX 2022009009A MX 2022009009 A MX2022009009 A MX 2022009009A MX 2022009009 A MX2022009009 A MX 2022009009A MX 2022009009 A MX2022009009 A MX 2022009009A
Authority
MX
Mexico
Prior art keywords
crystalline forms
enenitrile
oxetan
pent
pyrazolo
Prior art date
Application number
MX2022009009A
Other languages
English (en)
Inventor
Pasit Phiasivongsa
Kolbot By
Jean Baum
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022009009A publication Critical patent/MX2022009009A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se dan a conocer formas cristalinas del compuesto (I): (ver Fórmula) (I). También se dan a conocer composiciones farmacéuticas que las comprenden, métodos para tratar trastornos y afecciones en los que media actividad de BTK utilizando las mismas, y métodos para preparar el compuesto (I) y formas cristalinas del mismo.
MX2022009009A 2020-01-22 2021-01-21 Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo. MX2022009009A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964378P 2020-01-22 2020-01-22
PCT/US2021/014371 WO2021150723A1 (en) 2020-01-22 2021-01-21 Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022009009A true MX2022009009A (es) 2022-08-15

Family

ID=74672397

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009009A MX2022009009A (es) 2020-01-22 2021-01-21 Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.

Country Status (13)

Country Link
US (1) US11814390B2 (es)
EP (1) EP4093741A1 (es)
JP (1) JP2023511105A (es)
KR (1) KR20220130184A (es)
CN (1) CN115461341A (es)
AU (1) AU2021209884A1 (es)
BR (1) BR112022014149A2 (es)
CA (1) CA3164698A1 (es)
CO (1) CO2022009916A2 (es)
IL (1) IL294785A (es)
MX (1) MX2022009009A (es)
TW (1) TW202140484A (es)
WO (1) WO2021150723A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244562A1 (en) 2022-06-14 2023-12-21 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ710636A (en) * 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
EP3107544B1 (en) * 2014-02-21 2020-10-07 Principia Biopharma Inc. Salts and solid form of a btk inhibitor
CN110483521B (zh) 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
JP2023511105A (ja) 2023-03-16
US20210221818A1 (en) 2021-07-22
CN115461341A (zh) 2022-12-09
EP4093741A1 (en) 2022-11-30
CA3164698A1 (en) 2021-07-29
BR112022014149A2 (pt) 2022-09-27
CO2022009916A2 (es) 2022-09-30
TW202140484A (zh) 2021-11-01
WO2021150723A1 (en) 2021-07-29
AU2021209884A1 (en) 2022-09-15
KR20220130184A (ko) 2022-09-26
US11814390B2 (en) 2023-11-14
IL294785A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
EP1778240B1 (en) Dihydropteridinones for the treatment of cancer diseases
EP1599478B1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
HUE025285T2 (en) 2,4-di (aminophenyl) pyrimidine derivatives as PLK inhibitors
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BRPI0514865A (pt) processo para preparar um composto
NO20072984L (no) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
RS95404A (en) Thiazolidinones and the use thereof as polo-like kinase inhibitors
WO2005018557A3 (en) Substituted pyridinones
MX2016010754A (es) Sales y forma solida de un inhibidor btk.
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
MXPA04007470A (es) Piridinonas sustituidas.
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
NO20055092L (no) Substituerte pyrimidioner
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EP4302761A3 (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
BR112021023054A2 (pt) Formas cristalinas de um inibidor de btk
MX2022009009A (es) Formas cristalinas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h -pirazolo[3,4-d]pirimidin-1-il]piperidin-1-carbonil]-4-metil-4-[4 -(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
WO2020063788A8 (zh) Fgfr4抑制剂及其应用